Truvada and Tenofovir (TDF) lawsuits: where the Gilead HIV drug litigation actually stands as bellwethers approach

The Gilead Sciences tenofovir disoproxil fumarate (TDF) litigation represents one of the largest pharmaceutical mass torts currently pending without formal MDL consolidation. Approximately 25,000 to 26,000 plaintiffs are pending across two distinct procedural frameworks: an "organic" MDL in the U.S. District Court for the Northern District of California (where Gilead is headquartered) before Judge Jon S. Tigar, and the California state court coordinated proceeding (Judicial Council Coordination Proceeding No. 5043, "Gilead Tenofovir Cases and Coordinated Actions") in San Francisco Superior Court. The plaintiffs allege that Gilead's TDF-based HIV drugs, including Viread, Truvada, Atripla, Complera, and Stribild, caused kidney damage and bone density loss, and that Gilead knew about these risks as early as 2001 but withheld a safer alternative drug (tenofovir alafenamide, or TAF) to maximize profits from TDF-based medications before patents expired.

First, the failure-to-warn claim: Gilead allegedly knew TDF drugs caused kidney and bone toxicity but didn't adequately warn patients or healthcare providers. The FDA reprimanded Gilead in 2002 and 2003 for false claims about TDF safety, supporting plaintiffs' theory that Gilead had material knowledge of risks. Second, the alternative drug theory: Gilead allegedly developed TAF (a safer formulation) around 2004 but shelved the research, releasing TAF only when TDF patents were nearing expiration. Plaintiffs argue Gilead strategically delayed TAF to extend its TDF monopoly and maximize profits before generic TDF could enter the market. The California Supreme Court is currently reviewing whether plaintiffs must prove TDF itself was defective or whether evidence of withholding a safer alternative is sufficient under California product liability law, a ruling that will substantially affect the litigation's future.

The settlement landscape has been challenging for plaintiffs. In June 2024, Gilead announced a $40 million settlement for approximately 2,625 federal MDL plaintiffs, averaging just $12,500 per plaintiff. Many plaintiffs and their attorneys characterized the offer as inadequate given the severity of injuries (kidney failure, dialysis, bone fractures, osteomalacia). The federal settlement required 98% opt-in to take effect. Meanwhile, the much larger California state court litigation involving over 24,000 plaintiffs continues without comprehensive global settlement. Bellwether trials in California state court were scheduled for late 2025 and early 2026 to help guide future settlement negotiations. The federal MDL bellwether trial originally planned for November 2024 was delayed pending settlement discussions and the California Supreme Court review.

This is the science behind the TDF kidney and bone toxicity theory, the procedural history through the current bellwether and California Supreme Court phase, the eligibility framework for current and prospective plaintiffs, the settlement and litigation strategy considerations, and the implications of the pending California Supreme Court ruling for the broader litigation framework.

What is TDF and what is the alleged defect in Gilead's HIV drugs?

Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor used in several Gilead HIV medications, including Truvada, Viread, and Atripla. Plaintiffs allege TDF accumulates in kidney cells and causes kidney damage and bone density loss. They further allege Gilead shelved a safer formulation (TAF) for over a decade to maximize TDF profits before patents expired.

TDF is a critical component of HIV antiretroviral therapy:

TDF mechanism. Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor (NRTI) that blocks HIV's ability to replicate. The active compound (tenofovir) prevents HIV from using the reverse transcriptase enzyme needed for viral replication. TDF was the first oral form of tenofovir, approved by FDA in 2001. Before TDF, tenofovir required injection administration that limited clinical utility.

TDF metabolism issue. Once absorbed, TDF accumulates in kidney tubule cells at concentrations substantially higher than in blood plasma. The accumulation causes direct toxicity to renal tubular cells, leading to various forms of kidney damage. Similar mechanisms affect bone health through phosphate wasting and disrupted bone mineralization.

Gilead's TDF drugs covered in the litigation:

• Viread (tenofovir disoproxil fumarate alone)
• Truvada (TDF + emtricitabine, most prescribed)
• Stribild (TDF + emtricitabine + elvitegravir + cobicistat)
• Symfi Lo, Symfi (various TDF combinations)

All these drugs share the TDF component and the underlying toxicity issue.

TAF alternative. Tenofovir alafenamide (TAF) is a newer formulation of tenofovir that:

• Requires lower doses to be effective
• Accumulates less in kidney and bone tissue
• Has similar HIV efficacy to TDF
• Has substantially reduced kidney and bone toxicity

Gilead introduced TAF-based medications (Descovy, Genvoya, Odefsey) starting around 2015-2016. The TAF patent expires around 2032, providing Gilead additional monopoly period beyond TDF.

• Knew TDF caused kidney and bone damage from 2001
• Developed TAF around 2004 as a safer alternative
• Shelved TAF research to maximize TDF profits during TDF's patent period
• Released TAF only when TDF patents were nearing expiration (around 2015)
• Encouraged doctors to switch patients to TAF when generic TDF was about to enter the market
• This pattern extended Gilead's monopoly on tenofovir-based HIV medications

Internal corporate knowledge. Discovery has produced internal Gilead documents about TDF risks and TAF development. The FDA's 2002 and 2003 reprimands for false safety claims provide supporting evidence for plaintiffs' theory that Gilead had information about TDF risks that wasn't adequately disclosed.

What injuries are alleged in the TDF lawsuit?

Plaintiffs allege TDF causes both kidney and bone injuries. Kidney injuries range from acute kidney injury and chronic kidney disease to end-stage renal disease requiring dialysis or transplant. Bone injuries include osteoporosis, osteomalacia, and fractures (particularly hip and vertebral). Injury severity varies widely and directly affects case valuation.

Plaintiffs allege various kidney and bone injuries from TDF use:

• Acute kidney injury (AKI), sudden loss of kidney function, sometimes requiring temporary dialysis

• Chronic kidney disease (CKD), progressive kidney function decline

• End-stage renal disease (ESRD), requiring permanent dialysis or kidney transplant

• Fanconi syndrome, kidney tubule damage causing phosphate wasting, protein loss in urine, and metabolic acidosis

• Renal tubular acidosis, kidney's inability to acidify urine properly

• Osteomalacia, softening of bones due to vitamin D and phosphate metabolism problems

• Bone fractures, particularly hip, vertebral, and stress fractures

• Decreased bone mineral density (BMD), measurable through DEXA scans

• Declining estimated glomerular filtration rate (eGFR)

• Phosphaturia (phosphate wasting in urine)

Severity range. Injuries range from manageable kidney function changes to:

• Permanent kidney failure requiring lifelong dialysis
• Catastrophic bone fractures requiring surgery
• Permanent disability and reduced quality of life

The injury severity affects compensation valuation Some plaintiffs have undergone multiple hip replacements, complete tooth loss from osteomalacia, and ongoing dialysis with poor quality of life.

What is the procedural history of the Gilead TDF litigation?

The TDF litigation began with early lawsuits after Viread's 2001 FDA approval and grew into roughly 25,000 claims. Cases are split between a federal "organic" MDL before Judge Jon S. Tigar in the Northern District of California and California state coordinated proceeding JCCP 5043. Gilead's 2024 federal settlement of $40 million covered only about 2,625 plaintiffs, while bellwether trials and California Supreme Court review remain pending.

The litigation has developed through unusual procedural pathways:

2001-2018. TDF drugs in widespread clinical use.

February 2018. AIDS Healthcare Foundation (AHF) filed class action lawsuit on behalf of patients who purchased TDF drugs.

February 2019. Plaintiffs withdrew motion for formal MDL (would have been MDL 2881, In Re: Tenofovir Disoproxil Fumarate Products Liability Litigation). The withdrawal left the litigation without formal federal MDL consolidation.

April 2019. Northern District of California began consolidating federal TDF cases before Judge Jon S. Tigar for pretrial purposes. The consolidation created an "organic" or informal MDL through case transfers rather than JPML order.

August 2019. California state court coordinated proceeding established, Judge Kenneth R. Freeman ordered all California state TDF lawsuits coordinated before single judge in San Francisco Superior Court. Designated as Judicial Council Coordination Proceeding No. 5043 ("Gilead Tenofovir Cases and Coordinated Actions").

Throughout 2020-2023. Active discovery in both federal MDL and California state coordinated proceeding.

November 2023. Judge Tigar denied Gilead's motion to dismiss design defect and failure-to-warn claims in federal MDL, preserving plaintiffs' theories.

Judge Tigar tossed out eight of Gilead's experts after concluding their opinions were largely identical and probably ghostwritten by Gilead's lawyers.

June 2024.GILEAD SETTLEMENT OFFER. Gilead announced agreement in principle to pay $40 million to settle 2,625 federal MDL cases. The settlement required 98% opt-in to take effect.

Late 2024-Early 2025. Settlement administration for federal MDL cases. California state court litigation continued without comprehensive settlement. Federal bellwether trial originally planned November 2024 stayed pending settlement.

2024-2025.CALIFORNIA SUPREME COURT REVIEW. The California Supreme Court agreed to review key issue: whether plaintiffs must prove TDF itself was defective or whether evidence of withholding safer alternative TAF is sufficient under California product liability law.

2025-2026 California Supreme Court briefing. Plaintiffs' response due November 2025. Gilead's reply expected January 2026. Oral argument likely first half of 2026. Decision typically issued within 90 days after oral argument.

Late 2025-Early 2026 California state court bellwethers. Bellwether trials scheduled in California state court to test key issues and help guide future settlements.

Mid-2026 federal bellwethers. Federal MDL bellwether trials scheduled (specific dates subject to ongoing developments).

Current status. The litigation is in an unusual procedural posture awaiting:

• California Supreme Court ruling on liability standards
• California state court bellwether outcomes
• Resolution of remaining ~22,000+ plaintiffs not covered by $40 million federal settlement

What is the California Supreme Court reviewing in the TDF litigation?

The California Supreme Court is deciding whether TDF plaintiffs must prove the drug was defectively designed under traditional product liability standards, or whether showing Gilead withheld a safer alternative (TAF) for commercial reasons is sufficient. The ruling, expected mid-to-late 2026, will significantly affect both the Gilead litigation and future pharmaceutical product liability cases statewide.

The pending California Supreme Court review addresses a fundamental product liability question:

The legal issue. Whether plaintiffs in product liability cases involving allegedly safer alternative drugs must:

• Prove the original drug was defectively designed under traditional product liability standards, OR
• Show that the manufacturer withheld a safer alternative drug for non-medical reasons (commercial advantage)

Why this matters. The standard substantially affects the litigation:

Under traditional defective design standard. Plaintiffs would need to prove TDF itself was defectively designed compared to existing alternatives at the time of marketing. Given TDF was substantially safer and more effective than prior HIV medications, this could be difficult.

Under the "safer alternative" theory. Plaintiffs would need to show Gilead had a safer alternative (TAF) available but withheld it. This is easier to prove given the documented TAF development history.

• All pharmaceutical product liability litigation in California
• Litigation involving generic alternatives, follow-on drugs, and similar situations
• Investment and development incentives for safer drug formulations
• Industry strategy on drug release timing relative to patent protection

Expected ruling timeline. Oral argument first half of 2026, decision within 90 days after argument.

The California Supreme Court ruling will substantially affect both pending Gilead litigation and future pharmaceutical product liability cases in California. Industry-wide attention to the case reflects its precedential significance beyond the specific Gilead facts.

Who is eligible to file a TDF lawsuit?

To file a TDF claim, a plaintiff needs documented use of a Gilead TDF medication (such as Truvada, Viread, or Atripla), a qualifying kidney or bone injury that developed during or after use, supporting medical records and lab results, and a timely filing within the applicable statute of limitations. In California, the personal injury limitations period is two years, subject to the discovery rule.

Documented TDF medication use. Records showing the claimant took one of the Gilead TDF drugs:

Qualifying injury. Documented kidney or bone injury including:

Temporal relationship. The injury developed during or after TDF use. Long-term users (typically 1+ years on TDF) have stronger cases than short-term users.

• Medical records showing TDF prescription history
• Lab results documenting kidney function decline (serum creatinine, eGFR, urinalysis)
• DEXA scan results showing bone density loss
• Fracture records and orthopedic evaluations
• Treatment records for related complications
• Quality of life impact documentation

Statute of limitations analysis. Most states have 2-4 year limitations periods. California has 2-year limitations for personal injury under Cal. Civ. Proc. §335.1. The discovery rule applies, limitations begins when plaintiff knew or should have known about TDF's causal connection to the injury. Many plaintiffs only became aware of the TDF connection through litigation publicity, supporting discovery rule extension.

Federal vs. state court analysis. Plaintiffs may file in:

• Federal MDL (N.D. Cal.), for federal jurisdiction cases. Recent federal settlement may affect new filings.
• California state coordinated proceeding (JCCP 5043), for California residents or California-related cases
• Other state courts, for plaintiffs in other states (some plaintiffs in Missouri, Delaware, Florida, New York)

The choice of forum affects procedural timeline and potential outcomes. California state court has produced more favorable rulings for plaintiffs than federal MDL in some procedural matters.

What are the expected settlement amounts in the TDF lawsuit?

The 2024 federal settlement averaged only $12,500 per plaintiff and was widely criticized.

Settlement valuation is complex given the unusual procedural posture:

Federal MDL settlement (2024). $40 million for 2,625 plaintiffs averaged $12,500 per plaintiff. The amount was widely criticized as inadequate given injury severity.

• California Supreme Court ruling on liability standard
• California state court bellwether outcomes
• Federal MDL bellwether outcomes if not stayed
• Gilead's ongoing financial capacity annual TDF revenues exceeded $11 billion)

Tax implications. Personal injury settlements for physical injuries are generally tax-free under IRC §104(a)(2). Settlement allocation between physical injury (tax-free) and other components (potentially taxable) requires careful structuring. When plaintiffs face other tax issues, coordination with tax debt forgiveness procedures and NFTL withdrawal may be relevant to overall financial planning.

Gilead's financial capacity. Gilead generates annual revenues (over $25 billion in 2024) with strong financial position. The company can fund settlements without bankruptcy considerations affecting the litigation.

How does TDF litigation compare to other mass torts?

The TDF litigation stands out among pharmaceutical mass torts for its lack of formal MDL consolidation, its large California state coordinated proceeding (24,000+ plaintiffs), and a pending California Supreme Court review on a key liability standard. It shares features with Roundup, Zantac, and other major mass torts but presents unique procedural complexity.

• No formal MDL (motion withdrawn 2019), organic consolidation only
• Large California state coordinated proceeding (24,000+ plaintiffs)
• California Supreme Court reviewing key liability standard
• $40 million federal settlement covering only ~10% of plaintiffs
• Documented internal corporate knowledge of risks
• FDA reprimands supporting plaintiffs' theory
• Long-term clinical use providing extensive injury documentation
• Cancer patient analog: many plaintiffs needed HIV medications for life-saving treatment

The broader procedural framework for mass tort settlements is detailed in our overview of how mass tort litigation works. TDF represents one of the largest pharmaceutical mass torts pending without formal MDL consolidation.

What should TDF plaintiffs consider strategically?

TDF plaintiffs should retain experienced mass tort counsel, comprehensively document medication history and injuries with lab records and medical evidence, and monitor the pending California Supreme Court ruling on liability standards.

For prospective plaintiffs and those evaluating the litigation:

Engage experienced mass tort counsel immediately. The litigation is procedurally complex with multiple parallel tracks (federal organic MDL, California state coordinated proceeding, other state filings). Counsel with established TDF case experience handles these cases substantially better than general practitioners.

Document medication history comprehensively. The strongest cases include:

• Prescription records for all TDF medications used
• Duration of use for each medication

Document injury timeline carefully. Establish the timeline of:

• First symptoms of kidney or bone injuries
• Major complications (dialysis, transplant, fractures)

Lab evidence is critical. Comprehensive lab documentation strengthens cases substantially:

Coordinate with treating physicians. Nephrologists, endocrinologists, primary care physicians, and infectious disease specialists are important witnesses. Their support for the case theory strengthens cases.

Watch the California Supreme Court ruling carefully. The pending decision on liability standards will substantially affect:

Plan for multiple scenarios depending on the ruling.

Consider venue carefully. Choice between federal MDL participation and state court filing depends on:

Don't accept inadequate pre-bellwether settlements. The $40 million federal settlement averaged $12,500/plaintiff, inadequate for serious injuries. Larger state court litigation expects substantially higher per-plaintiff valuations following bellwether outcomes.

Address related tax considerations. Personal injury settlements for physical injuries are tax-free under §104(a)(2). If facing other tax issues, integrate with Voluntary Disclosure Practice considerations where appropriate.

Watch for wrongful death claims. Some TDF plaintiffs have died from kidney failure or related complications. Estates can pursue wrongful death claims with separate procedural framework. Family members may be eligible for compensation beyond the decedent's own claim.

Maintain current HIV treatment. TDF litigation shouldn't interfere with current HIV treatment. Most plaintiffs have already been switched to TAF-based medications by their healthcare providers. Maintain medication compliance for HIV management regardless of litigation status.

Consider University of Arizona Law expungement clinic analog for case assistance. Some law schools and legal aid organizations provide assistance for TDF cases. Resources may be available beyond traditional plaintiffs' firms.

Plan for the litigation's continuing development. New legal developments may substantially affect strategy:

The Gilead TDF litigation represents one of the most consequential pharmaceutical mass torts currently pending, with approximately 25,000+ plaintiffs across federal and state procedural frameworks. The theory, that Gilead knew TDF caused kidney and bone damage and withheld safer TAF alternative for commercial advantage, has documented support including FDA reprimands and internal corporate documents. The procedural posture is unusual (no formal MDL, large state coordinated proceeding, pending California Supreme Court review on liability standards), but the litigation is procedurally mature enough that meaningful resolution should follow bellwether outcomes and the California Supreme Court ruling. For plaintiffs with documented TDF use and kidney or bone injuries, the framework provides paths to compensation that should produce meaningful outcomes once the procedural complications resolve. Plaintiffs with strong documented cases should expect substantially higher valuations through state court litigation and post-bellwether settlements. The work for plaintiffs is in comprehensive documentation, engagement with experienced counsel familiar with both federal MDL and California state coordinated proceeding frameworks, patience with the extended procedural timeline, and informed monitoring of the California Supreme Court review and bellwether developments that will shape the litigation's resolution framework.